Profile data is unavailable for this security.
About the company
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
- Revenue in INR (TTM)83.73bn
- Net income in INR277.60m
- Incorporated2020
- Employees6.72k
- LocationPiramal Pharma LtdMUMBAI 400070IndiaIND
- Phone+91 223802300
- Websitehttps://www.piramal.com/businesses/piramal-pharma/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi India Ltd | 23.83bn | 4.30bn | 166.05bn | 2.17k | 38.64 | 24.26 | 35.48 | 6.97 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 171.82bn | 940.00 | 179.24 | -- | 154.92 | 12.38 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Eris Lifesciences Ltd | 22.62bn | 3.80bn | 185.98bn | 3.08k | 48.96 | -- | 30.47 | 8.22 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 190.99bn | 995.00 | 34.59 | -- | 20.51 | 2.79 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 219.16bn | 14.86k | 34.80 | -- | 24.21 | 3.48 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Pfizer Ltd | 22.25bn | 6.09bn | 249.64bn | 1.72k | 41.03 | -- | 37.27 | 11.22 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Laurus Labs Ltd | 50.54bn | 1.48bn | 251.98bn | 6.01k | 170.39 | -- | 45.59 | 4.99 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Natco Pharma Ltd. | 42.21bn | 16.37bn | 265.28bn | 4.02k | 16.21 | -- | 14.54 | 6.28 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | 14.87 |
Concord Biotech Ltd | 10.38bn | 3.13bn | 272.12bn | 1.38k | 86.91 | -- | 74.16 | 26.22 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 273.91bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Piramal Pharma Ltd | 83.73bn | 277.60m | 288.80bn | 6.72k | 1,038.68 | -- | 37.06 | 3.45 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 294.67bn | 5.31k | 51.30 | -- | 40.10 | 8.20 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Gland Pharma Ltd | 58.58bn | 7.22bn | 296.63bn | 4.22k | 41.08 | -- | 27.13 | 5.06 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 309.37bn | 1.05k | 128.52 | -- | 104.55 | 33.11 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
IPCA Laboratories Ltd | 82.12bn | 5.77bn | 363.98bn | 17.34k | 63.10 | -- | 38.36 | 4.43 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
Ajanta Pharma Ltd | 43.33bn | 8.54bn | 391.16bn | 7.84k | 46.19 | -- | 39.51 | 9.03 | 67.79 | 67.79 | 343.97 | -- | -- | -- | -- | 5,523,445.00 | -- | 16.61 | -- | 20.47 | 75.01 | 73.22 | 19.71 | 19.31 | -- | -- | -- | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
Holder | Shares | % Held |
---|---|---|
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 29 Jul 2024 | 93.53m | 7.06% |
East Bridge Capital Management L.P.as of 06 Sep 2024 | 47.77m | 3.60% |
The Caisse de d�p�t et placement du Qu�becas of 29 May 2023 | 43.31m | 3.27% |
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2024 | 24.44m | 1.84% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 21.16m | 1.60% |
Canara Robeco Asset Management Co. Ltd.as of 31 Aug 2024 | 12.87m | 0.97% |
Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Aug 2024 | 9.87m | 0.74% |
Dimensional Fund Advisors LPas of 05 Sep 2024 | 9.44m | 0.71% |
BlackRock Fund Advisorsas of 05 Sep 2024 | 8.44m | 0.64% |
Mahindra Manulife Investment Management Pvt Ltd.as of 31 Aug 2024 | 6.84m | 0.52% |